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ABSTRACT
Neuroendocrine carcinomas of the breast are a rare and distinct entity that is not routinely encountered in clinical practice. The 
diagnosis of primary neuroendocrine breast carcinoma is mainly a diagnosis of exclusion as the metastatic disease is more common 
a possibility. The algorithmic approach in the evaluation of such tumors includes the clinical and radiological examination of the 
breast lumps followed by correlation with Histopathological study and Immunohistochemistry tests. We report a case of primary 
neuroendocrine carcinoma of the breast in a 64-year-old female who presented with breast lump for one month duration.
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Primary Neuroendocrine carcinoma (NEC) of the breast is a great diagnostic challenge as it lacks the characteristic clinical and radiological features. This under-recognized 
entity constitutes less than 0.1 % of all breast cancers and less 
than 1% of all neuroendocrine tumors [1]. These tumor cells 
have characteristic salt and pepper chromatin. The diagnosis 
of NEC requires confirmation by an ancillary method of 
immunohistochemistry (IHC) which demonstrates the presence 
of neuroendocrine differentiation by using markers such as 
synaptophysin, chromogranin [2]. However, before diagnosis, the 
possibility of a metastatic tumor should be ruled out by appropriate 
imaging studies along with a thorough clinical history correlation 
to avoid misdiagnosis and overtreatment. Optimal treatment 
strategy in such tumors is not standardized as only a few cases 
of primary neuroendocrine carcinomas have been documented in 
the literature. Hence due to the rarity and to increase the literature 
evidence, we report a case of neuroendocrine carcinoma of the 
breast in a sexagenarian woman.
CASE REPORT
A 64-year-old post-menopausal multiparous woman presented to the 
surgery outpatient department with a lump in the left breast for one 
month. It was insidious in onset and progressively increased in size. 
There was no significant past medical, family or surgical history. 
Her vitals were stable. On physical examination, a 3x3x2 cm 
lump was present in the lower inner quadrant which was firm 
to hard in consistency and not freely mobile. The overlying skin 
and nipple-areola were unremarkable. There was no significant 
axillary lymphadenopathy. The right breast was normal. Other 
systemic examination was normal.
Ultrasound of both breasts showed an echo poor lesion with 
irregular margins in the left breast and Breast Imaging-Reporting 
and Data System (BI-RADS) assessment category 5 was given 
which is highly suggestive of malignancy. Fine needle aspiration 
cytology (FNAC) of the left breast lump was performed yielding 
scant material which showed a few macrophages and adipose 
tissue against a hemorrhagic background. There were no atypical 
cells in the smears studied. Hence, a biopsy was suggested if 
clinically suspicious of malignancy. Later Trucut biopsy of the 
left breast lump was done which was reported as carcinoma 
with neuroendocrine differentiation. IHC did show positivity 
for chromogranin, synaptophysin and CK 7. Needle core biopsy 
and IHC findings were consistent with the diagnosis of small cell 
neuroendocrine carcinoma. With the aid of the Positron Emission 
Tomography (PET) scan, the possibility of metastatic disease was 
ruled out.
The patient underwent left modified radical mastectomy. 
Gross examination revealed a circumscribed lesion within the 
breast measuring 3x2.5x2 cm which had a grey-white cut surface 
(Fig. 1a and 1b). Microscopy showed a neoplasm composed of 
cells arranged in nests and trabeculae separated by fibrous septa. 
No mucinous areas or solid papillary growth were seen. Albeit the 
morphology strongly favored the neuroendocrine differentiation, 
we still ruled out the possible other differentials having a similar 
picture like in invasive lobular carcinoma with alveolar pattern 
and endocrine Ductal carcinoma in situ.
Hence based on morphology and IHC confirmation, the 
diagnosis of invasive carcinoma with neuroendocrine features 
was given (Fig. 1c and 1d). The postoperative period was 
uneventful. The patient was comfortable at the time of discharge 
and discharged with a drain in situ. The patient received 
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adjuvant chemotherapy (Epirubicin, Endoxan, and Fluorouracil), 
radiotherapy, and hormonal therapy. At one-year imaging and 
clinical follow-up, the patient had no evidence of metastasis.
DISCUSSION
Neuroendocrine differentiation in breast carcinomas was first 
described by Feyrter and Hartmann in 1963, based on positive silver 
staining in mucinous carcinomas of the breast [3]. The primary NEC 
of the breast is under-recognized owing to the lack of established 
consensus on the degree of neuroendocrine differentiation required 
for the diagnosis. Two histogenesis theories such as arising from 
pre-existing endocrine cells and differentiation processes within 
the breast have been postulated regarding the origin of such tumors 
in the breast [3]. An association of these tumors with mucinous 
histology, solid papillary growth pattern and invasive lobular 
carcinoma has been reported in the literature [4].
The diagnosis is complex due to the absence of characteristic 
clinical and image findings [4]. The most common sites include 
the lungs and gastrointestinal tract, however, occurrence in the 
breast is rare. The first case series on carcinoid tumors of the 
breast was published by Cubilla and Woodruff in 1977 [5]. There 
is no significant difference in clinical presentation and usually 
occurs in the elderly age group [6]. Tang et al reported that 
neuroendocrine differentiation was missed in up to 69% (51 of 
74) of breast carcinomas [7]. The radiological findings are not 
typical and may look similar to one of the other types of breast 
tumors. Neuroendocrine differentiation in breast carcinomas is 
often overlooked in routine practice.
The presence of ductal carcinoma in situ adjacent to the 
tumor can strongly establish and reconfirm the primary origin 
of the breast. Before designating a case as NEC of the breast, 
utmost care must be taken to rule out the possibilityof metastatic 
cancer from the lung, gastrointestinal tract (GIT), pancreas, and 
cervix as histomorphology of both primary and metastasis remain 
similar [8].
ER and PR can be positive in both primary and metastatic 
disease. IHC markers such as mammaglobin and GCDFP help 
in specifically identifying primary carcinoma of the breast 
[9]. GATA3, mammaglobin, and GCDFP15 serve as the most 
specific markers in establishing the primary origin of the breast 
[10]. Based on the size of the tumor and lymph nodal status, the 
management of such an entity is usually surgery [11]. The benefits 
of adjuvant therapy have not been demonstrated in the literature 
because of the low occurrence of the disease but invariably all the 
patients with primary NEC of the breast are treated with routine 
chemotherapy cycles.
CONCLUSION
In the era of evolving clinical perspectives, a pathologist occupies the 
forefront of inactive patient management. It’s really important to be 
borne in mind that neuroendocrine carcinomas do occur in breast and 
even if subtle changes of neuroendocrine differentiation exist it must 
be confirmed with Immunohistochemistry analysis. Additionally, 
it is critical to distinguish primary and metastatic neuroendocrine 
carcinomas as the former is still very rare than the latter.
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Figure 1: (a and b) Gross picture of the tumour; (c and d)
The neoplastic cells are small arranged in nests with dispersed 
chromatin; H&E- 40x.
